A total of 518 patientswho underwent DES implantation for off-label indications and did not have any major adverse cardiac events (MACE) during the first year were analyzed. The occurrence of MACE, including cardiac death, myocardial infarction (MI), stentthrombosis and target vessel revascularization, were evaluated for a median 1179 days (interquartile range 769-1541) after the first year.